Ensign Peak Advisors
UTHR icon

Ensign Peak Advisors’s United Therapeutics UTHR Stock Holding History

Ensign Peak Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15M Sell
25,292
-1,543
-6% -$768K 0.03% 343
2025
Q4 		$13.1M Sell
26,835
-6,446
-19% -$3M 0.02% 356
2025
Q3 		$14M Sell
33,281
-1,134
-3% -$381K 0.02% 383
2025
Q2 		$9.89M Sell
34,415
-2,979
-8% -$890K 0.02% 475
2025
Q1 		$11.5M Sell
37,394
-263
-0.7% -$90.1K 0.02% 426
2024
Q4 		$13.3M Buy
37,657
+640
+2% +$235K 0.02% 398
2024
Q3 		$13.3M Buy
37,017
+3,340
+10% +$1.13M 0.02% 406
2024
Q2 		$10.7M Buy
33,677
+7,205
+27% +$1.91M 0.02% 432
2024
Q1 		$6.08M Sell
26,472
-6,018
-19% -$1.36M 0.01% 574
2023
Q4 		$7.14M Sell
32,490
-1,236
-4% -$285K 0.01% 533
2023
Q3 		$7.62M Sell
33,726
-2,084
-6% -$480K 0.02% 461
2023
Q2 		$7.91M Buy
35,810
+15,250
+74% +$3.38M 0.02% 480
2023
Q1 		$4.6M Buy
20,560
+4,518
+28% +$1.11M 0.01% 597
2022
Q4 		$4.46M Sell
16,042
-60,015
-79% -$15.2M 0.01% 588
2022
Q3 		$15.9M Buy
76,057
+11,615
+18% +$2.6M 0.04% 298
2022
Q2 		$15.2M Sell
64,442
-740
-1% -$150K 0.04% 307
2022
Q1 		$11.7M Buy
65,182
+6,675
+11% +$1.27M 0.02% 391
2021
Q4 		$12.6M Sell
58,507
-14,053
-19% -$2.76M 0.02% 412
2021
Q3 		$13.4M Buy
72,560
+25,235
+53% +$4.97M 0.03% 377
2021
Q2 		$8.49M Sell
47,325
-2,165
-4% -$412K 0.02% 476
2021
Q1 		$8.28M Buy
49,490
+1,309
+3% +$218K 0.02% 469
2020
Q4 		$7.31M Sell
48,181
-261,873
-84% -$34.4M 0.02% 491
2020
Q3 		$31.3M Buy
310,054
+168,249
+119% +$18.5M 0.08% 218
2020
Q2 		$17.2M Buy
141,805
+96,521
+213% +$10.9M 0.05% 323
2020
Q1 		$4.29M Buy
45,284
+7,595
+20% +$722K 0.01% 552
2019
Q4 		$3.32M Buy
+37,689
New +$3.32M 0.01% 799

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ensign Peak Advisors's UTHR Position: Q1 2026 in Review

Ensign Peak Advisors reduced its United Therapeutics (UTHR) stake by 5.7% in Q1 2026, selling an estimated $768K and leaving 25,292 shares worth $15M. The position accounts for 0.03% of the portfolio, ranked #343.

Ensign Peak Advisors first reported a position in UTHR in Q4 2019 and has held it in 26 quarters since. The position peaked at $31.3M in Q3 2020. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Ensign Peak Advisors held 25,292 shares of United Therapeutics worth $15M as of Q1 2026.
  • Ensign Peak Advisors sold 1,543 United Therapeutics shares in Q1 2026, an estimated $768K.
  • United Therapeutics made up 0.03% of Ensign Peak Advisors's portfolio in Q1 2026, its #343 holding.
  • Ensign Peak Advisors first reported a position in United Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's United Therapeutics position peaked at $31.3M in Q3 2020.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.